

Advertising by Google

Treatment for Thyroid

Leading Ear Nose Throat Specialist, Dr YH Goh. Mt Elizabeth Medical Ctr www.ENToms.com

Do You Have Leukemia?

Learn What Causes Leukemia, Symptoms & Treatments Leukemia. LeukemiaFacts.com

Cancer

Parkway Cancer Centre - Providing holistic & comprehensive treatment. www.ParkwayHealth.com

ProMedDx BioRepository

Human Biologics for Research Let us help expedite your research. www.ProMedDx.com

How To Fight All Cancers

Learn how, & where to get products that counter the causes of cancer. www.CancerFightingStrategies.com

Lymphoma Treatments

Top 7 Sites For Lymphoma Treatment Ranked and Ready. lymphomatreatment.net

Breast Cancer Treatments

A Guide to the different types of Breast Cancer Treatments. www.YourHealthPortal.com

China Stem Cell News

News on Research and Treatments With Patient Videos and Blogs www.stemcellschina.com

Virtual Colonoscopy News

For VC and radiology professionals News & information resource on VC VirtualColonoscopy.AuntMinnie.com

Stem cell Reagent

Transfection reagent for Embryonic stem cells



🚹 Add to Google 📲 🔛 📳 🖪 👂 🍃 🛗 투 🚹 🔘 🔃

Aggressive therapy best for certain acute myeloid leukemia patients

Medical Studies/Trials Published: Sunday, 5-Aug-2007



A new study suggests that acute leukemia patients whose cancer cells show a genetic change that usually predicts a swift return of the disease following remission may remain disease-free longer when given aggressive therapy.

The findings apply to people with acute myeloid leukemia (AML) whose cancer cells have normal-looking chromosomes and a gene mutation called MLL-PTD.

Typically, these AML patients responded poorly following treatment with older standard therapies, often relapsing within a year. Of AML patients with normal chromosomes who lack the mutation, on the other hand, four in 10 are cured.

The new study suggests that treating patients who have the mutation with an aggressive therapy such as an autologous stem cell transplant while they are in remission might significantly extend their disease-free survival.


An autologous transplant uses stem cells taken from the patient's own blood.

The research was led by investigators at the Ohio State University Comprehensive Cancer Center. It is part of a larger study sponsored by the Cancer and Leukemia Group B (CALGB), a clinical cooperative group composed of oncologists from academic medical centers and community hospitals across the nation.

The findings were published in a recent issue of the journal Blood.

"Our data is the first to show that AML patients with normallooking chromosomes and this mutation do as well when treated aggressively as patients who don't have the mutation," says principal investigator Clara D. Bloomfield, professor of internal medicine and an internationally known AML specialist.

About 13,400 new cases of AML are expected this year, and



www.synvolux.com

Nanotechnology Investment

New nanotechnology that may reverse aging and treat disease www.504bank.com/telodpo.asp

Blood Pressure Too High?

Find out How A Natural Remedy Can Lower Your High Blood Pressure! FaithMedsInstitute.com

Global Stem Cells Events

Senior level conferences for the worldwide Stem Cells industry www.terrapinn.com

Cancer Screening

Colorectal Cancer can be Detected & Early Screening can be Life-Saver! www.ColorectalCentre.com

Patient Self-Care Tools

Drive Evidence-Based Care Engage & Activate Patients www.chroniccare.org about half will have cancer cells with chromosomes that show distinctive damage. The nature of that damage helps doctors determine a patient's therapy and estimate the patient's prognosis.

The remaining AML cases have cancer cells with normallooking chromosomes. These cells lack the microscopic chromosome damage that guide therapy.

In 1994, however, a team of researchers that included Bloomfield discovered the MLL-PTD mutation in these patients. It was the first clinically useful marker to be identified in cases of AML with normal-looking chromosomes, and it was found to predict a short remission and poor response to therapy. About 8 percent of AML patients with normal-looking chromosomes have the mutation.

"Studies done eight to 10 years ago showed that nearly 100 percent of these patients relapsed and died within two years," says first author Susan P. Whitman, a research scientist at Ohio State's Comprehensive Cancer Center.

This retrospective study set out to learn whether aggressive therapy provided through two CALGB clinical trials benefits patients with the mutation. It evaluated 238 people aged 18 to 59 with AML and normal-looking chromosomes. Of these, 24 (10 percent) had the MLL-PTD mutation.

All patients received an initial aggressive chemotherapy regimen (i.e., induction therapy) to induce remission. Those who achieved remission then received further aggressive therapy (i.e., consolidation therapy), usually an autologous stem cell transplant, with a few receiving intensive chemotherapy.

Of the 24 patients with the mutation, 22 had a complete remission. Of those, 13 relapsed within 1.4 years, but nine (41 percent) remained in remission when the study ended, with disease-free periods ranging from two to almost eight years.


"We believe that the use of aggressive consolidation therapy may have contributed to the reduced number of early relapses in these patients," Bloomfield says.

"We still must do larger studies to confirm these findings, to better understand this disease and to develop curative targeted therapies."

http://www.osu.edu

Would you like to register for our weekly NO-NONSENSE Medical News Letter? At the end of each week we'll send you an email containing links to the most popular articles (by page impression) from your chosen categories that appeared on News-Medical.Net in that week. You will NOT be bombarded with advertising and you CAN unsubscribe at any time. Click here for more information.





News-Medical. Net provides this medical news service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

©2007 News-Medical.Net